40results about How to "Meet the needs of large-scale clinical applications" patented technology

The invention relates to an anti-human-CPR (C reactive protein) antibody and an application thereof. Multiple antibodies are prepared and subjected to matched screening, and an antibody combination (P24 and P03) with sensitivity and specificity meeting the requirement is obtained; meanwhile, mass production of the antibody combination is facilitated, and the requirement of later large-scale clinical application can be met. The antibody combination is subjected to debugging optimization work by a detection system, a time-resolved immunofluorescence chromatography quantitative detection card for human CPR is obtained and is simple and convenient to operate, and the sensitivity, the specificity and related detection performance of the time-resolved immunofluorescence chromatography quantitative detection card can meet the requirement of human clinical sample detection.

The present invention relates to a human beta2-microglobulin quantitative test card. The invention prepares a plurality of antibodies and performs paired screening to obtain a group of antibody combinations (BM12 and BM17) having sensitivity and specificity which can meet requirements of the quantitative test card. At the same time, the test card is convenient for mass production, and can meet theneeds of large-scale clinical applications in the future. The antibody combination is debugged and optimized in the detection system to obtain a colloidal gold immunochromatographic quantitative testcard for human beta2-microglobulin which is easy to operate, sensitive, specific and has related detection performance meeting the detection of human blood or urine samples.

The invention relates to an anti-human neutrophil gelatinase-associated lipocalin antibody and its application in detection test paper cards. The present invention prepares a variety of antibodies and conducts pair screening to obtain a group of antibody combinations (NG02 and NG19) that can meet the needs of sensitivity and specificity; meanwhile, it is convenient for mass production and can meet the needs of large-scale clinical application in the future. Debugging and optimizing the detection system of the above antibody combinations, and obtaining a colloidal gold immunoassay for human neutrophil gelatinase-associated lipocalin that is easy to operate, sensitive, specific and related detection performance can meet the detection of human blood or urine samples Chromatographic quantitative detection card.

The invention relates to a novel anti-human myoglobin antibody and an application thereof in a detection kit, and belongs to the field of immunochemistry. According to the invention, a plurality of antibodies are prepared, and paired screening is carried out to obtain an antibody combination (M26 and M08) which meets requirements in sensitivity and specificity. Meanwhile, the antibody combinationis convenient for mass production and can meet the requirement of future large-scale clinical application. The debugging optimization work of a detection system for the antibody combination is carriedout to completely meet the application requirements of preparing fluorescent rapid detection test paper cards for human myoglobin. The fluorescent rapid detection test paper cards are simple and convenient to operate, and accord with commercial application indexes in sensitivity, specificity and related detection performance.

The invention relates to a fluorescent quantitative test strip for human tissue kallikrein 1 (hK1) and related antibodies. According to the invention, a plurality of monoclonal antibodies are prepared and are paired and screened, so an antibody combination (A24 and A32) with sensitivity and specificity meeting demands is obtained; and the antibody combination can be conveniently produced in a large scale and can meet demands of large-scale clinical application in the future. The antibody combination is subjected to adjustment and optimization of a detection system so as to obtain the time-resolved immunofluorescent chromatographic quantitative test strip for human tissue kallikrein 1 with the advantages of simple operation and good sensitivity, specificity and related detection performance.

The invention, which belongs to the field of in vitro diagnosis, relates to an immunohistochemical detection kit for human CD26 and clinical application thereof. According to the disclosed immunohistochemical detection kit, a novel anti-human-CD26 antibody is employed; the heavy chain variable region contains following complementarity determining regions: HCDR1, HCDR2, and HCDR3 having the amino acid sequences shown by SEQ ID NO:1, 2, and 3 respectively; and light chain variable region sequences contain following complementarity determining regions: LCDR1, LCDR2, LCDR3 having the amino acid sequences shown by SEQ ID NO:4, 5, 6. According to the invention, the performance requirement of the immunohistochemical kit can be met by related detection performances like the specificity of the anti-human-CD26 antibody; the antibody can be a mouse antibody or a recombinantly expressed chimeric human antibody and is convenient to product in a large scale; with the recombinantly expressed chimerichuman antibody, the human anti-mouse antibody response is reduced and the non-specific adsorption is reduced; and thus the need of large-scale clinical application can be met. In the application of the CD26 target drug, the effect of precise treatment is realized by using the immunohistochemical detection kit.

The invention relates to an anti-human CD26 antibody, and preparation and a commercial application of the anti-human CD26 antibody, and belongs to the field of in vitro diagnosis. A heavy chain variable region of the anti-human CD26 antibody comprises the following complementarity-determining regions: HCDR1 with an amino acid sequence shown as SEQ ID NO: (sequence identifier number) 1, HCDR2 withan amino acid sequence shown as SEQ ID NO: 2, and HCDR3 with an amino acid sequence shown as SEQ ID NO: 3; and a light chain variable region of the anti-human CD26 antibody comprises the following complementarity-determining regions: LCDR1 with an amino acid sequence shown as SEQ ID NO: 4, LCDR2 with an amino acid sequence shown as SEQ ID NO: 5, and LCDR3 with an amino acid sequence shown as SEQ ID NO: 6. Relevant detection performance, such as specificity, of the anti-human CD26 antibody can meet performance requirements of an immunohistochemical kit; and a chimeric humanized antibody constructed by the applicant on a basis of the antibody is more convenient to recombine, express and produce massively, reduces a human anti-mouse antibody response and non-specific adsorption and can meet requirements of large-scale clinical application.

The invention relates to a human C-reactive protein colloidal gold quantitative detection card, two anti-human C-reactive protein (CRP) antibodies adopted for the card, and a preparation method of the antibodies. Multiple antibodies are prepared by an inventor, paired and screened, and antibody combinations (P20 and P02) with sensitivity and specificity both meeting requirements are obtained. Mass production is convenient, and the requirements of large-scale clinical application in future can be met. The antibody combinations are subjected to debugging optimization work of a detection system, the human C-reactive protein colloidal gold immunochromatography quantitative detection card which is easy and convenient to operate and has sensitivity, specificity and relevant detection performance greatly improved is obtained, and the clinical sample detection requirements are completely met.

The invention relates to an anti-human procalcitonin antibody and application thereof. A variety of antibodies are prepared, matched and screened, and an antibody combination with the sensitivity and specificity meeting requirements is obtained; meanwhile, mass production is convenient, and the requirement for large-scale clinic application in the future can be met. Debugging and optimization work of a detection system is carried out on the antibody combination, and a human PCT time-resolved immunofluorescence chromatography quantitative test card which is easy and convenient to operate is obtained, wherein the sensitivity, specificity and relevant detection performance can meet human clinic sample detection.

The invention relates to an anti-human tissue kallikrein 1 antibody and an application thereof. The invention provides a plurality of monoclonal antibodies. Through matching screening, an antibody combination (A24 and A32) with sensitivity and specificity meeting certain demand is obtained. The antibody combination is convenient for mass production, such that the need of large-scale clinical application in future can be satisfied. The antibody combination is subjected to detection system debugging optimization, such that a human tissue kallikrein 1 enzyme-linked immune quantitative detection kit, a human tissue kallikrein 1 colloidal gold immunochromatographic quantitative detection card and a human tissue kallikrein 1 time-resolved immunofluorescence chromatographic quantitative detection card, which are simple to operate and the sensitivity, selectivity and related detection performances of which can satisfy human plasma sample detection, can be obtained.

The invention relates to a colloidal gold quantitative test strip for human tissue kallikrein 1 (hK1) and related antibodies. According to the invention, a plurality of monoclonal antibodies are prepared and are paired and screened, so an antibody combination (A24 and A32) with sensitivity and specificity meeting demands is obtained; and the antibody combination can be conveniently produced in a large scale and can meet demands of large-scale clinical application in the future. The antibody combination is subjected to adjustment and optimization of a detection system so as to obtain the colloidal gold immunochromatographic quantitative test strip for human tissue kallikrein 1 with the advantages of simple operation and good sensitivity, specificity and related detection performance.

The present invention relates to anti-human procalcitonin antibody and applications thereof. According to the present invention, a variety of antibodies are prepared, and pairing screening is performed to obtain the antibody combination having sensitivity and specificity, wherein the sensitivity and the specificity can meet the requirements; mass production is convenient, and the large-scale clinical application requirements in the future can be met; and the debugging optimization work of the detection system is performed on the antibody combination to obtain the time-resolved immunofluorescence chromatography quantitative detection card of the human procalcitonin, wherein the operation of the detection card is convenient, and the sensitivity, the specificity and the related detection performance of the detection card can meet the human clinical sample detection.

The invention relates to anti-human C-reactive protein antibody and application thereof. The invention prepares a plurality of antibodies, and performs pairing and screening to obtain the antibody combination (P24 and P03) with which sensitivity and specificity can satisfy the requirement. The antibody is convenient to produce in large quantities, and can meet the requirement of clinical application in large-scale. The time-resolved fluoroimmunoassay chromatography quantitative detection card of human C-reactive protein having meeting clinical sample detection performances such as sensitivity, specificity and related detection performance is obtained by means of adjusting and optimizing of detection system for the antibody combination, and the detection card is easy and simple to operate.

The invention relates to an immunohistochemical detection kit for human CD26 and its clinical application, belonging to the field of in vitro diagnosis. The immunohistochemical detection kit disclosed in the present invention adopts a brand-new anti-human CD26 antibody, and its heavy chain variable region contains the following complementarity determining regions: the amino acid sequences are as shown in SEQ ID NO: 1, 2, 3 respectively HCDR1, HCDR2, HCDR3; and their light chain variable region sequences contain the following complementarity determining regions: LCDR1, LCDR2, LCDR3 shown in SEQ ID NO: 4, 5, 6, respectively. The specificity of the anti-human CD26 antibody used in the present invention can meet the performance requirements of the immunohistochemical kit, and it can be a mouse antibody or a recombinantly expressed chimeric human antibody, which is convenient for mass production, wherein the recombinantly expressed chimeric antibody Combined with human antibodies to reduce human anti-mouse antibody reactions and non-specific adsorption, it can also meet the needs of large-scale clinical applications. When using the CD26 target drug, the immunohistochemical kit of the present invention can be used together to achieve the effect of precise treatment.

The invention relates to a test paper card for fluorescent quantitative detection of human PCT (procalcitonin). According to the invention, various antibodies are prepared and subjected to pairing screening, and an antibody combination with sensitivity and specificity both meeting requirements is obtained; mass production of the test paper card is facilitated, and the requirement for large-scale clinical application in the future can be met. The antibody combination is subjected to a debugging and optimizing work of a detection system, the time-resolved immunofluorescence chromatography quantitative detection card which is simple and convenient to operate and applied to the human PCT is obtained, and the sensitivity, the specificity and related detection performance of the card can meet the requirements of human clinical sample detection.

The invention relates to an ELISA quantitative detection kit for detecting human tissue kallikrein 1 (hK1) and related antibodies. According to the invention, a plurality of monoclonal antibodies are prepared and are paired and screened, so an antibody combination (A24 and A32) with sensitivity and specificity meeting demands is obtained; and the antibody combination can be conveniently produced in a large scale and can meet demands of large-scale clinical application in the future. The antibody combination is subjected to adjustment and optimization of a detection system so as to obtain the ELISA quantitative detection kit for human tissue kallikrein 1 with the advantages of simple operation and good sensitivity, specificity and related detection performance.

The invention relates to a novel anti-human MYO antibody and its application in a detection kit, belonging to the field of immunochemistry. The present invention prepares a variety of antibodies, and performs paired screening to obtain antibody combinations (M26 and M08) that can meet the needs of sensitivity and specificity; meanwhile, it is convenient for mass production and can meet the needs of large-scale clinical applications in the future. The debugging and optimization of the detection system for the above-mentioned antibody combination can fully meet the application requirements of the preparation of the fluorescent rapid detection test paper card for human myoglobin. Indicators for commercial application.

The invention relates to an anti-human-CPR (C reactive protein) antibody and an application thereof. Multiple antibodies are prepared and subjected to matched screening, and an antibody combination (P24 and P03) with sensitivity and specificity meeting the requirement is obtained; meanwhile, mass production of the antibody combination is facilitated, and the requirement of later large-scale clinical application can be met. The antibody combination is subjected to debugging optimization work by a detection system, a time-resolved immunofluorescence chromatography quantitative detection card for human CPR is obtained and is simple and convenient to operate, and the sensitivity, the specificity and related detection performance of the time-resolved immunofluorescence chromatography quantitative detection card can meet the requirement of human clinical sample detection.